Highest-materiality recent filing
Guardant Health Q1 revenue rises 48% to $301.7 million, boosts 2026 guidance
Revenue increased 48% to $301.7M driven by Oncology revenue growth of 36% and Screening revenue surge to $41.6M.
Guardant Health Q4 revenue $281.3M (+39% YoY); 2026 revenue guided $1.25-1.28B
Q4 total revenue $281.3M (+39% YoY); Oncology tests 79k (+38%), Screening tests 38k.
Guardant Health reports Q4 revenue $280M (+39% YoY); full year revenue $981M (+33%)
Q4 oncology tests ~79,000 (+38% YoY); full year ~276,000 (+34%).
Guardant Health raises ~$717M via upsized equity and convertible debt offerings
Public offering of 3,833,332 shares at $90/share (incl. underwriter option), net proceeds ~$327.2M.
Guardant Health Q3 revenue $265.2M (+39% YoY); raises FY2025 revenue guidance to $965-$970M
Q3 total revenue $265.2M (+39% YoY); GAAP net loss $92.7M ($0.74/share), non-GAAP net loss $48.3M ($0.39/share).
Guardant Health Q2 revenue $232.1M (+31% YoY); raises FY2025 guidance to $915-925M
Q2 total revenue $232.1M (+31% YoY); Oncology $158.7M (+22%), Screening $14.8M, Biopharma $56.0M (+28%).
Guardant Health Q1 revenue $203.5M (+21% YoY); raises FY2025 revenue guidance to $880-$890M
Q1 total revenue $203.5M, +21% YoY; oncology $150.6M (+20%, 59K tests); screening $5.7M (9K Shield tests); biopharma $45.4M (+21%).
Full-year 2024 revenue $739M (+31% YoY); net loss $436.4M ($3.56 loss per share); non-GAAP net loss $247.2M ($2.01 loss per share).
Guardant Health issues $600M 1.25% convertible notes due 2031; retires $659.3M of 0% notes due 2027
Exchanged $600M new 1.25% convertible notes due 2031 for $659.3M of existing 0% notes due 2027.
Guardant Health exchanges $659.3M of 0% 2027 notes for $600M of 1.25% 2031 notes; plans $45M buyback
Issues $600M of 1.25% Convertible Senior Notes due Feb 15, 2031, exchanging for $659.3M of 0% Convertible 2027 Notes.
Guardant Health reports preliminary Q4 revenue ~$200M (+29% YoY); FY24 revenue $737M (+31%)
Total revenue Q4 ~$200M (+29% YoY); full year ~$737M (+31% YoY).
Guardant Health Q3 revenue $191.5M (+34% YoY); raises FY 2024 revenue guidance to $720-725M
Revenue $191.5M (+34% YoY); GAAP net loss $107.8M ($0.88/shr), Non-GAAP net loss $55.0M ($0.45/shr).
Guardant Health enters ATM sales agreement with Jefferies for up to $400M equity offering
Entered Open Market Sale Agreement with Jefferies LLC for at-the-market offering of common stock.
Guardant Health Q2 revenue up 29% to $177.2M, raises FY2024 guidance; FDA approves Shield CRC test
Revenue $177.2M (+29% YoY); precision oncology revenue $166.5M (+33%).
Guardant Health's Shield blood test gets FDA approval for colorectal cancer screening in ages 45+
Shield is first blood test approved by FDA as a primary screening option for colorectal cancer.
FDA advisory panel strongly recommends approval of Guardant's Shield blood test for CRC screening
FDA advisory panel voted 8-1 that Shield is safe, 6-3 that it is effective, and 7-2 that benefits outweigh risks.
Guardant Health Q1 revenue up 31% to $168.5M; raises 2024 revenue guidance to $675-685M
Revenue $168.5M (+31% YoY); net loss narrowed to $115M ($0.94 loss per share) from $133.5M.
On October 21, 2024, the Board of Directors (the “Board”) of Guardant Health, Inc. (the “Company”) increased the number of directors on the Board to ten and appointed Roberto Mignone., as a Class I director of the Company, to be effective as of October 21, 2024.
On July 17, 2024, the Board of Directors (the “Board”) of Guardant Health, Inc. (the “Company”) increased the number of directors on the Board to nine and appointed Manuel Hidalgo Medina, M.D., Ph.D., as a Class II director of the Company, to be effective as of July 17, 2024.
Max materiality 0.90 · Median 0.75 · Most common event earnings